This Analyst Sees 34% Upside For SRPT Stock — Here's Why They Expect A Sustained Rally Next
Analysts at Wolfe Research upgraded Sarepta to ‘Outperform’ from ‘Peer Perform,’ with a price target of $27.
Read the full articleYou might also wanna read
Sensata Technologies Holding (NYSE:ST): A Decent Value Play with a Strong Margin of Safety
Sensata Technologies (NYSE:ST) offers a compelling value opportunity with a low P/E of 12.95, solid profitability, and decent health. This u
Moderna Is Up More Than 70% in a Month After a 9-0 FDA Vote. Wall Street's Average Price Target Says It Should Fall 44%. What Gives?
When a stock and the analysts covering it disagree this sharply, one of them is about to be wrong.
Veralto price target raised by $3 at Wolfe Research, here's why
See the rest of the story here . thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The F
SPX Technologies price target raised by $7 at Wolfe Research, here's why
See the rest of the story here . thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The F
Bernstein Raises Arm Stock Price Target to $500, Citing Agentic AI Growth Prospects
Bernstein's increased price target of 66.7% on ARM stock is mainly due to agentic AI tailwinds.
barchart.com·19d agoBernstein Raises Arm Stock Price Target to $500, Citing Agentic AI Growth Prospects
Bernstein's increased price target of 66.7% on ARM stock is mainly due to agentic AI tailwinds.
barchart.com·19d agoModerna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout
Moderna, ImmunityBio, and Sarepta are all cratering today despite bullish recent news and no negative catalysts in sight, leaving investors
Comments
Sign in to join the conversation.
No comments yet. Be the first.